Ami Fadia
Stock Analyst at Needham
(3.66)
# 834
Out of 4,711 analysts
365
Total ratings
46.79%
Success rate
7.43%
Average return
Main Sectors:
Stocks Rated by Ami Fadia
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NBIX Neurocrine Biosciences | Reiterates: Hold | n/a | $135.42 | - | 11 | Dec 20, 2024 | |
| JAZZ Jazz Pharmaceuticals | Reiterates: Buy | $207 | $122.97 | +68.33% | 26 | Dec 12, 2024 | |
| COGT Cogent Biosciences | Downgrades: Hold | $15 | $7.84 | +91.33% | 21 | Dec 11, 2024 | |
| MRUS Merus | Reiterates: Buy | $85 | $41.85 | +103.11% | 25 | Dec 9, 2024 | |
| RVMD Revolution Medicines | Maintains: Buy | $68 → $62 | $44.06 | +40.72% | 20 | Dec 6, 2024 | |
| SAGE Sage Therapeutics | Reiterates: Hold | n/a | $5.61 | - | 18 | Nov 20, 2024 | |
| BIIB Biogen | Downgrades: Hold | $270 | $146.47 | +84.34% | 36 | Nov 18, 2024 | |
| BPMC Blueprint Medicines | Reiterates: Buy | $135 | $90.14 | +49.77% | 24 | Nov 15, 2024 | |
| IMRX Immuneering | Reiterates: Buy | $15 | $2.00 | +650.00% | 10 | Nov 14, 2024 | |
| AXSM Axsome Therapeutics | Reiterates: Buy | $130 | $90.73 | +43.28% | 6 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $23 | $10.85 | +111.98% | 5 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $22 | $10.31 | +113.39% | 31 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $28 | $16.87 | +65.98% | 6 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $151 | $76.52 | +97.33% | 7 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $38 | $14.68 | +158.86% | 15 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $33 | $12.79 | +158.01% | 17 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $100 | $83.45 | +19.83% | 25 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $52 | $34.28 | +51.69% | 29 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $12 → $16 | $0.46 | +3,378.26% | 2 | Feb 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $63 → $75 | $18.98 | +295.15% | 7 | Jan 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $15 → $23 | $1.77 | +1,171.19% | 4 | Oct 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $64 → $63 | $25.75 | +144.66% | 5 | Sep 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $12 → $5 | $3.39 | +47.49% | 2 | Jan 30, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Market Perform | n/a | $22.09 | - | 9 | Oct 1, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $22 | $1.58 | +1,292.41% | 4 | Jan 3, 2018 |
Neurocrine Biosciences
Dec 20, 2024
Reiterates: Hold
Price Target: n/a
Current: $135.42
Upside: -
Jazz Pharmaceuticals
Dec 12, 2024
Reiterates: Buy
Price Target: $207
Current: $122.97
Upside: +68.33%
Cogent Biosciences
Dec 11, 2024
Downgrades: Hold
Price Target: $15
Current: $7.84
Upside: +91.33%
Merus
Dec 9, 2024
Reiterates: Buy
Price Target: $85
Current: $41.85
Upside: +103.11%
Revolution Medicines
Dec 6, 2024
Maintains: Buy
Price Target: $68 → $62
Current: $44.06
Upside: +40.72%
Sage Therapeutics
Nov 20, 2024
Reiterates: Hold
Price Target: n/a
Current: $5.61
Upside: -
Biogen
Nov 18, 2024
Downgrades: Hold
Price Target: $270
Current: $146.47
Upside: +84.34%
Blueprint Medicines
Nov 15, 2024
Reiterates: Buy
Price Target: $135
Current: $90.14
Upside: +49.77%
Immuneering
Nov 14, 2024
Reiterates: Buy
Price Target: $15
Current: $2.00
Upside: +650.00%
Axsome Therapeutics
Nov 13, 2024
Reiterates: Buy
Price Target: $130
Current: $90.73
Upside: +43.28%
Nov 13, 2024
Reiterates: Buy
Price Target: $23
Current: $10.85
Upside: +111.98%
Nov 13, 2024
Reiterates: Buy
Price Target: $22
Current: $10.31
Upside: +113.39%
Nov 7, 2024
Reiterates: Buy
Price Target: $28
Current: $16.87
Upside: +65.98%
Nov 7, 2024
Reiterates: Buy
Price Target: $151
Current: $76.52
Upside: +97.33%
Oct 31, 2024
Reiterates: Buy
Price Target: $38
Current: $14.68
Upside: +158.86%
Oct 31, 2024
Reiterates: Buy
Price Target: $33
Current: $12.79
Upside: +158.01%
Oct 31, 2024
Reiterates: Buy
Price Target: $100
Current: $83.45
Upside: +19.83%
Oct 30, 2024
Reiterates: Buy
Price Target: $52
Current: $34.28
Upside: +51.69%
Feb 1, 2021
Maintains: Outperform
Price Target: $12 → $16
Current: $0.46
Upside: +3,378.26%
Jan 21, 2021
Downgrades: Market Perform
Price Target: $63 → $75
Current: $18.98
Upside: +295.15%
Oct 1, 2020
Maintains: Market Perform
Price Target: $15 → $23
Current: $1.77
Upside: +1,171.19%
Sep 17, 2020
Maintains: Outperform
Price Target: $64 → $63
Current: $25.75
Upside: +144.66%
Jan 30, 2019
Downgrades: Market Perform
Price Target: $12 → $5
Current: $3.39
Upside: +47.49%
Oct 1, 2018
Upgrades: Market Perform
Price Target: n/a
Current: $22.09
Upside: -
Jan 3, 2018
Initiates: Outperform
Price Target: $22
Current: $1.58
Upside: +1,292.41%